New hope for Hard-to-Treat colorectal cancer: Virus-Based therapy joins chemo
NCT ID NCT07446322
First seen Mar 13, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This study tests whether adding a virus-based drug called pelareorep to standard chemotherapy (FOLFIRI plus bevacizumab) can shrink tumors better than chemo alone in people with a specific type of advanced colorectal cancer (RAS-mutated, MSS). About 60 adults whose cancer worsened after first-line treatment will participate. The goal is to improve response rates and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Central Alabama Research
RECRUITINGHomewood, Alabama, 35209, United States
-
Summit Health Cancer Center
RECRUITINGFlorham Park, New Jersey, 07932, United States
Conditions
Explore the condition pages connected to this study.